By Fineline Cube D3 Bio announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for its investigational therapy elisrasib (D3S-001), a next-generation KRAS G12C inhibitor indicated for first-line advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE/NMPA (China) |
| Designation Type | Breakthrough Therapy Designation (BTD) |
| Product | Elisrasib (D3S-001) |
| Indication | First-line treatment of advanced NSCLC with KRAS G12C mutations |
| Designation Date | May 2026 |
| Next Steps | Expedited regulatory review pathway; potential accelerated approval |
Drug Profile & Mechanism of Action
- Molecule: Next-generation small-molecule KRAS G12C inhibitor (oral)
- Target: KRAS G12C protein in its GDP-bound (OFF) state
- Innovation: Covalently binds to KRAS G12C, blocking nucleotide cycling and inhibiting oncogenic signaling pathways
- Key Differentiators:
- Potent activity with adequate target engagement at clinically relevant exposure levels
- Central nervous system (CNS) penetration capability – critical for addressing brain metastases in NSCLC
- Intellectual Property: Global patents held by D3 Bio
Clinical Development Status
| Program Element | Details |
|---|---|
| Current Phase | Global Phase II studies |
| Study Arms | Monotherapy and combination therapy |
| Target Population | KRAS G12C-mutant solid tumors |
| Tumor Types | Non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer |
| Preclinical Highlights | Demonstrated potent anti-tumor activity, adequate target engagement, and CNS penetration |
The BTD is based on compelling preclinical data showing elisrasib’s ability to achieve sufficient target engagement at clinically achievable doses while demonstrating CNS penetration—a significant advantage for NSCLC patients who frequently develop brain metastases.
Market Impact & Outlook
- NSCLC Landscape: KRAS G12C mutations occur in approximately 13% of NSCLC cases, representing a significant unmet medical need with limited targeted therapy options in first-line settings.
- Competitive Positioning: As a next-generation KRAS G12C inhibitor with CNS penetration, elisrasib may address limitations of earlier-generation inhibitors that lack adequate brain exposure.
- Regulatory Advantage: BTD provides intensive guidance from CDE, eligibility for rolling review, and potential priority review upon NDA submission.
- Global Strategy: Parallel development in multiple tumor types positions D3 Bio to capture broader market opportunities beyond NSCLC.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory designations, clinical development, and commercial expectations for elisrasib. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech